ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The red-wine compound resveratrol has received a lot of attention as a possible therapy to prevent heart disease and cancer with few side effects in patients at high risk for the diseases. Now a new study reports that resveratrol protects against colorectal cancer in mice, but more so at low, not high, doses (Sci. Transl. Med. 2015, DOI: 10.1126/scitranslmed.aaa7619). Karen Brown of the University of Leicester, in England, and colleagues studied mice with genetic mutations that made them susceptible to developing adenomas in their intestines. Compared with animals not receiving resveratrol, those getting a high dose had a 25% smaller total tumor volume, while the mice receiving a low dose had a 52% smaller volume. But the researchers observed this pronounced low-dose effect only in mice that ate a high-fat diet for reasons that the team doesn’t fully understand. The findings, Brown says, suggest that resveratrol’s effects don’t increase linearly with dosage.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter